Table 3.

Patient characteristics, treatment, and outcome

No.	Sex	Age at Dx (mo)	Primary site	Results of surgery	M stagea)	Treatment after surgery and response	Tumor status before HDCT1	Tumor status after HDCT1	Tumor status after HDCT2	Outcome	Site of failure
1	Female	20	PF	GTR	1	AB–PD	-	-	-	3 mo dead, PD at 2 mo	P+M
5	Female	3	PF	NTR	3	ABABAB–HDCT1–HDCT2–PD	PR	PR	PR	15 mo dead, PD at 14 mo	M
8	Female	29	T	STR	3	ABABAB–HDCT1–HDCT2–RT (23.4-30.6-0)b)–Relapse	PR	CR	CCR	23 mo dead, relapse at 22 mo	P+M
9	Female	9	PF	STR	3	ABABAB–PD–Surgery (STR)–HDCT1–HDCT2–RT (23.4-30.6-0)–PD	PR2c)	PR	PR	37 mo dead, PD at 7 mo	P+M
10	Female	2	PF	STR	2	ABA–PD	-		-	6 mo dead, PD at 5 mo	P+M
2	Female	177	T	NTR	0	AB–RT (23.4-30.6-0)–PD–Surgery (GTR)–A–PD–RT (0-30.0-0)–HDCT1–PD	PD	PD	-	12 mo dead, PD at 6 mo	P
3	Female	180	F	GTR	0	AB–RT (23.4-30.6-0)–ABAB–HDCT1–HDCT2	CCR	CCR	CCR	108+ mo alive, Ds free	-
4	Male	181	P-O	STR	0	AB–PD–RT (23.4-30.6-0)–Surgery (NTR)–PD	-	-	-	9 mo dead, PD at 2 mo	P
6	Female	154	F	GTR	0	AB–RT (23.4-30.6-0)–ABAB–HDCT1–HDCT2	CCR	CCR	CCR	85+ mo alive, Ds free	-
7	Male	79	T	STR	3	AB–RT (30.6-23.4-0)–ABAB–HDCT1–HDCT2	PR	CR	CCR	73 mo dead, relapse at 73 mo	P
11	Female	43	LV	STR	3	PD after surgery–AB–RT (36.0-18.0-0)–PD–A–HDCT1–PD–HDCT2–PD	PD	PD	PD	14 mo dead, PD at 1 mo	M
12	Female	93	SC	STR	3	RT (36.0-18.0-14.4)–ABABAB–HDCT1–HDCT2	PR	PR	CR	43+ mo alive, Ds free	-
13	Male	171	TV	Bxd)	0	RT (23.4-30.6-0)–ABABAB–HDCT1–Surgery (GTR)e)	PR	PR	-	39+ mo alive, Ds free	-

Dx, diagnosis; HDCT1, first high-dose chemotherapy; HDCT2, second high-dose chemotherapy; PF, posterior fossa; GTR, gross total resection; A, CECV (carboplatin+etoposide+cyclophosphamide+vincristine) regimen; B, CEIV (carboplatin+etoposide+ifosfamide+vincristine) regimen; PD, progression; P, primary site; M, metastatic site; NTR, near total resection; PR, partial response; T, temporal lobe; STR, subtotal resection; RT, radiotherapy; CR, complete response; CCR, continuous CR; PR2, second PR; F, frontal lobe; Ds, disease; P-O, parieto-occipital lobe; LV, lateral ventricle; SC, spinal cord; TV, third ventricle; Bx, biopsy; CSF, cerebrospinal fluid.

^a)M stage; 0, no leptomeningeal seeding; 1, positive CSF cytology; 2, seeding at cerebrum; 3, seeding at spinal cord,

^b)RT dose (Gy) to craniospinal-primary (boost)- gross seeding nodule (boost),

^c)PR2 was achieved by second-look surgery, not by chemotherapy or RT,

^d)Only biopsy was possible due to severe tumor bleeding during surgery and cognitive function worsened after surgery,

^e)No viable tumor cells were found.